A $75 million at-the-market equity shelf, disclosed by Pulse Biosciences, Inc. (Nasdaq: PLSE) in an 8-K filed August 6, 2026, gives management the option to raise capital on its own schedule without locking in a price. The facility, structured as an equity distribution agreement with Mizuho Securities USA LLC as sales agent, runs until it is drawn or terminated, leaving a dilution ceiling over shareholders for the duration.
How the at-the-market facility works
Under the Sales Agreement, Mizuho will use commercially reasonable efforts to sell Pulse Biosciences common stock at prevailing market prices, at prices related to prevailing market prices, or at negotiated prices. Transactions may run through ordinary broker trades, block trades, or sales to or through a market maker on the Nasdaq Capital Market. Pulse will pay Mizuho a commission of up to 3.0% of the gross sales price on any shares actually sold, and will reimburse Mizuho for certain specified expenses.
The shares are registered under a Form S-3 (File No. 333-293596) that Pulse filed with the Securities and Exchange Commission on February 19, 2026, which became effective on February 27, 2026. A prospectus supplement was filed on August 6, 2026 in connection with the Sales Agreement. Baker & Hostetler LLP, counsel to the company, provided the legal opinion on the validity of the issuance.
What management retains
Pulse Biosciences holds the right to set price, time, and size limits on any sales, and may suspend solicitations entirely at any time. The company is under no obligation to sell a single share. Chief Executive Officer Paul A. LaViolette signed the filing on behalf of the Hayward, California company. That optionality is the core argument for the structure: management can access equity capital when the stock price cooperates and pull back when conditions shift, without the fixed commitment a traditional offering requires.
The counterargument
The counterargument carries real weight. A program of this size represents a standing supply overhang. Any buyer in the secondary market knows Mizuho may be selling into the same session at the prevailing price, which can cap price momentum and widen the effective spread between bids and offers. The 3.0% commission adds cost on each transaction. A traditional fixed-price offering would have distributed that drag differently.
On balance
On balance, the facility trades shareholder certainty for management flexibility. The line to watch is the pace at which Pulse draws on the $75 million capacity. The Sales Agreement sets no schedule and no minimum. Execution rests entirely with the company.